目的 探討舒眠片聯(lián)合酒石酸唑吡坦片治療失眠癥的療效。方法 選擇2020年9月—2021年9月在天津市泰達(dá)醫(yī)院就診的60例失眠患者，隨機(jī)分為對(duì)照組和治療組，每組各30例。對(duì)照組口服酒石酸唑吡坦片，10 mg/次，1次/d。在對(duì)照組的基礎(chǔ)上，治療組睡前口服舒眠片，3片/次，2次/d。兩組治療14 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時(shí)間，匹茲堡睡眠質(zhì)量調(diào)查表（PSQI）評(píng)分，血清因子白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）水平，及不良反應(yīng)情況。結(jié)果 治療后，治療組臨床有效率為96.67%，明顯高于對(duì)照組的73.33%（P＜0.05）。治療后，治療組臨床癥狀好轉(zhuǎn)時(shí)間均早于對(duì)照組（P＜0.05）。治療后，兩組PSQI評(píng)分、IL-1β、TNF-α水平均明顯降低（P＜0.05），且治療后治療組PSQI評(píng)分、IL-1β、TNF-α水平均明顯低于對(duì)照組（P＜0.05）。治療期間，治療組不良反應(yīng)發(fā)生率（6.67%）明顯低于對(duì)照組（16.67%，P＜0.05）。結(jié)論 舒眠片聯(lián)合酒石酸唑吡坦片治療失眠癥療效顯著，可有效改善患者的睡眠質(zhì)量，并能改善機(jī)體炎癥反應(yīng)，且安全有效。

Objective To investigate the therapeutic of Shumian Tablets combined with zolpidem in treatment of insomnia. Methods Patients (60 cases) with insomnia in Tianjin TEDA Hospital from September 2020 to September 2021 were randomly divided into control and treatment group, and each had 30 cases. Patients in the control group were po administered with Zolpidem Tartrate Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Shumian Tablets before bed on the basis of the control group, 3 tablets/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, the PSQI scores, the levels of serum IL-1β and TNF-α, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.67%, which was significantly higher than that of the control group (73.33%) (P < 0.05). After treatment, the time of improvement of clinical symptoms in the treatment group was earlier than that in the control group (P < 0.05). After treatment, PSQI score, IL-1β and TNF-α levels in 2 groups were significantly decreased (P < 0.05), and PSQI score, IL-1β and TNF-α levels in treatment group were significantly lower than those in control group (P < 0.05). During the treatment, the adverse reaction rate in the treatment group (6.67%) was significantly lower than that in the control group (16.67%, P < 0.05). Conclusion The combination of Shumian Tablets and Zolpidem Tartrate Tablets can significantly improve the curative effect, effectively improve the sleep quality of patients, and improve the inflammatory response of the body, and it is safe and effective.

R971